2 Day Training Course | FDA QMSR and the Key Elements of QSIT cGMP Inspection and Audits for Medical Device Manufacturers (ONLINE EVENT: September 22-23, 2025)

Explore the FDA's QMSR, key elements of QSIT cGMP inspections, and changes to medical device regulations. This seminar covers 21 CFR 820, CAPA, P&PC, risk management under ISO 14971, and internal vs. FDA audits. Essential for manufacturers aiming for compliance and US market success.

Dublin, July 10, 2025 (GLOBE NEWSWIRE) -- The "The FDA QMSR and the Key Elements of QSIT cGMP Inspection and Audits for Medical Device Manufacturers" training has been added to ResearchAndMarkets.com's offering.

The FDA QMSR and the Key Elements of QSIT cGMP Inspection and Audits for Medical Device Manufacturers

What are U.S. FDA cGMP requirements for the manufacture of medical devices for sale in the US? Discuss the key Quality System Regulation / Quality Management System requirements of 21 CFR 820, the Quality System Regulation. QSIT for FDA inspections. And anticipated changes to a QMSR.

This 2-day seminar will examine the 14 key elements of the Medical Device cGMPs, 21 CFR 820, the Quality System Regulation, the 7 key elements, and the defining 4 elements, as defined and evaluated by the FDA's QSIT. Product development and manufacturing ('realization') and its compliance and documentation. Design Control, the Device History File, the Device Master Record and the Device History Record are defined.

Corrective and Preventive Action (CAPA) requirements and key components. Production and Process Control (P&PC) expectations. Verification and Validation, including software

Why and How? Risk management under ISO 14971, a major component of the proposed QMSR, will also be considered. Differing approaches to compliance inspections / audits internally by the company and externally by the FDA. A discussion of FDA's new proposed revised 820 incorporating ISO 13485 into the new QMSR will also be included.

Why You Should Attend:

Global companies must meet US FDA 21 CFR 820 (The QSR) requirements in order to sell such devices in the US, no matter where they are manufactured. These companies must pass FDA compliance inspections (audits) to 21 CFR 820. The cGMPs mandate 15 key systems and procedures that must be followed and documented to allow cleared / approved product to be sold commercially in the US. Of those 15, the FDA focuses on 7, and places extreme emphasis on 4, per QSIT.

Why? What does compliance look like? What are the benefits to the company for compliance? What role does the Risk Management File (ISO 14971) and Use Engineering File (IEC 62366-1) play in conformance and day-to-day compliance? How does failure to comply result in adulterated product, 483 Observations, Warning Letters, and worse? What are key components of a cGMP-compliant QMS, a Risk Management File, and a Use Engineering / Human Factors File, and their interrelationships?

Who Should Attend:

• Senior Management
• Quality Assurance Departments
• Regulatory Affairs Departments
• Research and Development Departments
• Manufacturing Departments
• Engineering Departments
• Operations Departments
• Production Departments
• All personnel involved in the U.S. FDA-regulated medical device spec development and manufacturing environments
• Especially those involved in new medical device / combination product development, line extensions, and incremental product improvements
• Those evaluating changes in light of the DHF / cGMPs and documenting actions in harmony with the regulations

Key Topics Covered:

DAY 1

Session 1

• The U.S. FDA's 21 CFR 820, the QSR, the Device cGMPs/QMS, QSIT

Session 2

• The Documentation Requirements
• Design Controls
• Management Responsibility

Session 3

• Production and Process Controls
• Corrective and Preventive Action (CAPA)
• Materials Control
• Facilities and Equipment Control

DAY 2

Session 1

• DHF Required Contents
• Verification and Validation, including software - Why and How?

Session 2

• The Risk Management File (ISO 14971) and its role
• The Use Engineering File (IEC 62366-1) and its role

Session 3

• Expected QMS Records
• The DMR and DHR

Session 4

• FDA Inspection/Audit Focus
• New QMSR rule changes to 21 CFR 820 and ISO 13485

Speaker

John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 36 years experience in U.S. FDA-regulated industries, 22 of which are as an independent consultant. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files, CAPA systems and analysis.

He's held positions in Manufacturing Engineering , QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. He writes a recurring column for the Journal of Validation Technology. John is a graduate of UCLA.

For more information about this training visit https://www.researchandmarkets.com/r/sjvtde

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900